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1. Abstract 
Epigenetics studies heritable changes in gene expression patterns, which are 
dependent on processes such as DNA methylation, histone modifications or RNA 
directed silencing mechanisms. Epigenetic therapy seems to be effective for 
treatment of such reversible modifications and is promising for cancer therapy.  
Anaplastic large cell lymphoma (ALCL) is a non-Hodkin lymphoma of T-cell origin. In 
80% of cases, a chromosomal translocation (t 2;5) occurs, which generates the 
oncogenic fusion protein NPM-ALK. The fusion protein acts as a constitutive active 
kinase and is involved in important signaling pathways, such as JAK/STAT, PI3K and 
MAPK, which play a role in controlling cell proliferation and survival. 
Our study aimed at studying epigenetic drugs for the treatment of ALCL. We have 
tested two promising drugs, namely 5-Aza-2'-deoxycytidine (Aza), a DNA 
methyltransferase inhibitor and MS-275, a histondeacetylase inhibitor, in vitro using 
human ALCL cell lines and in vivo in a Xenograft model .  
Treatment with Aza using the three ALCL cell lines Karpas-299 (ALK positive), SR-
786 (ALK positive) and Mac-2A (ALK negative), showed decreased cell number and 
survival, increased apoptosis and decreased methylation patterns of selected target 
genes. In vivo studies in NOD/SCID mice using the human ALK positive cell line 
Karpas-299 showed decreased or no tumor growth, increased apoptosis and lower 
cell proliferation upon treatment with  Aza. As a consequence of this, we observed 
decreased promoter DNA methylation and reduced DNMT1 protein levels in treated 
mice.  
In vitro treatment with MS-275 in the ALCL cell lines resulted in decreased cell 
number and survival. ALK positive ALCL cell lines showed lower expression of NPM-
ALK after 4 days of treatment. However, in vivo Xenograft experiments with MS-275 
showed less pronounced effects including a slight growth reduction, but no weight 
reduction compared to control mice, although acetylation of histones was slightly 
increased in treated mice. 
Based on these findings, Aza showed promising results in the treatment of ALK 
positive ALCL both in vitro and in vivo, whereas the use of MS-275 in vitro showed 
inhibition of cancer cell growth, but results could not be repeated in vivo. 
In conclusion, targeting epigenetic enzymes like DNMTs and HDACs could provide a 
possible option for therapy in this disease. 
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2. Zusammenfassung 
Epigenetische Modifikationen sind vererbbar und können Genexpressionmuster bei 
verschiedenen Krebszelllinien verändern. Diese Veränderungen beinhalten Prozesse 
wie DNA Methylierung, Histonmodifikationen oder RNA-abhängige Mechanismen. 
Die Behandlung von solchen reversiblen Modifikationen könnte eine effektive 
Therapie in malignen Tumoren darstellen. 
Das Großzellige-anaplastische Lymphom (ALCL) zählt zu den nicht Hodgkin T–Zell 
Lymphomen. Die chromosomale Translokation (t 2;5) generiert das onkogene 
Fusionsprotein NPM-ALK und ist in 80% aller ALCL-betroffenen Personen 
vorhanden. Dieses Fusionsprotein kontrolliert verschiedene Signaltransduktionswege 
wie JAK/STAT, PI3K und MAPK und spielt eine wichtige Rolle bei der Kontrolle von 
Zellproliferation und Überleben. 
Die Entwicklung neuer, zukünftiger Therapien für die Behandlung von ALCL und die 
Forschung im Bereich der epigenetischen Arzneimittel waren die Ziele unserer Arbeit. 
Im Zuge unserer Forschung testeten wir die zwei erfolgversprechenden Arzneimittel, 
5-Aza-2-deoxycytidine (Aza), ein DNA-Methyltransferase Inhibitor, und MS-275, ein 
Histondeactetylase Inhibitor, sowohl in vitro als auch in vivo. 
Die  Behandlung mit Aza führte in allen drei getesteten ALCL Zelllinien zu 
verminderter Zellzahl, erhöhter Apoptose und verminderter Methylierung von 
Tumorsuppressorgenen. 
In vivo wurde ein Xenograft Experiment durchgeführt wobei NOD/SCID Mäuse und 
die ALK positive Zelllinie Karpas-299 verwendet wurden. Nach der Behandlung 
konnten wir eine deutliche Verminderung der Tumorgröße feststellen, in einigen 
Fällen waren die Mäuse sogar tumorfrei. Das Tumorgewebe aus den behandelten 
Mäusen war stark apoptotisch und die Zellproliferation war vermindert. Ebenso 
beobachteten wir einen allgemeinen Rückgang der DNA-Methylierung, sowie ein 
verringertes Proteinlevel von DNMT1 in den behandelten Mäusen. 
Die in vitro Behandlung mit MS-275 von ALCL Zelllinien führte zu reduzierter Zellzahl 
und vermindertem Zellüberleben. Die ALK positiven Zelllinien zeigten niedrigere 
NPM-ALK  Proteinexpression nach viertägiger Behandlung mit MS-275.  In vivo 
konnte allerdings nur eine leichte Reduktion der Tumorgröße, aber keine Reduktion 
von Tumorgewicht, beobachtet werden, obwohl die Acetylierung in Tumoren nach 
Behandlung mit MS-275 etwas erhöht war. 
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Diese Ergebnisse zeigen, dass Aza ein vielversprechendes Therapeutikum in ALK 
positiven  ALCL  darstellt, während MS-275 nur einen Effekt in vitro, aber nicht im 
Xenograft Modell zeigte. 
Zusammenfassend kann gesagt werden, dass Medikamente, die eine Rolle bei der 
Regulierung von epigenetischen Enzymen haben, möglicherweise als zukünftige 
Behandlungsmethode in Betracht gezogen werden können. 
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3. Introduction 
3.1 Epigenetics – Modern Definition 
Epigenetics is the study of heritable changes in gene expression, which are not 
encoded in the sequence of the genome. In contrast to genetic changes that are 
irreversible, epigenetic changes are reversible (1). There are three main epigenetic 
mechanisms: RNA directed silencing, posttranslational histone modifications and 
DNA methylation (2) of which the latter two will be discussed below. 
3.2 DNA –Methylation 
DNA methylation in mammals occurs at the cytosine residue of CpG dinucleotides 
and leads to heritable silencing of genes and non-coding genomic regions by either 
preventing access or recruiting regulatory proteins to DNA (3).  
Methylated CpG dinucleotides are prevalent in heterochromatic regions, such as 
repetitive sequences, centromeric repeats and retrotransposon elements. On the 
other hand  CpG-rich DNA stretches called „„CpG islands“ (2), which are found in 
approximately 60% of promoters of mammalian genes, are usually unmethylated  
and the corresponding gene is not silenced (3). 
 A reason why DNA is heavily methylated at repetitive sequences might be to repress 
i.e. parasitic DNA sequences, which are foreign sequences incorporated into the host 
DNA (4). This defensive role of DNA methylation is also important for the genomic 
stability for silencing non-coding and transposable DNA elements (5). Thus, DNA 
methylation might have evolved as a defensive mechanism against foreign invading 
DNA. 
 3.2.1 Mammalian DNA methyltransferases 
The enzymes that catalyze the transfer from S-Adenosylmethionine (SAM) to DNA 
are called DNA methytransferases. There are de novo and maintenance 
methyltranseferases. De novo methyltransferses can target unmethylated DNA, 
whereas maintenance methyltransfterases show a preference for hemimethylated 
DNA. 
In mammals there are five reported members of the DNMT family: DNMT1, DNMT2, 
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DNMT3a, DNMT3b, and DNMT3L (3). 
De novo methyltransferases DNMT3A and DNMT3B can work independently from S-
phase and establish methylation patterns during embryonic development. They are 
highly expressed in embryonic stem (ES) cells and to a lesser extend in differentiated 
cells (6). 
The maintenance methyltransferase DNMT1 works mainly on hemimethylated DNA 
during replication, but it has been recently reported to also have de novo activity (3). 
DNMT2 contains only the conserved catalytic domain and was suggested to be 
involved in the methylation of tRNAs and silencing of transposons in flies (3,7). 
DNMT3L has no DNMT activity but is involved in genomic imprinting processes by 
interacting with DNMT3a/3b (3). 
3.3 Histone Modifications  
There are two main forms of chromatin: the decondensed and early replicating 
euchromatin and the inaccessible, gene poor and late replicating heterochromatin. 
Chromatin is organized in nucleosome particles of a histone octamer around which 
147 bp of DNA is wrapped (8).  
The protein octamer is build of two molecules of each canonical histone protein H2A, 
H2B, H3 and H4. Histones are small, basic proteins. They contain a globular C-
terminal domain and a flexible N-terminal tail (9). Post-translational modifications 
usually occur at the histone tail, although the globular domains can also undergo 
such modifications. Different chemical groups, such as methyl-, acetyl- and 
phosphate-groups, and different degrees of methylation like mono-, di- and tri-
methylation are involved in these types of modifications (8). There are also other 
modifications that have recently been identified, such as ubiquitination, sumoylation, 
ADP-ribosylation, biotinylation and proline isomerisation (10-12). Important enzymes 
involved in histone modifications are histone acetyltransferases (HATs), which are 
targeting lysine residues by adding acetyl groups, and histone deacetylases 
(HDACs), which are involved in removing these groups (13). Serine or threonine 
residues can be targeted by kinases, which add phosphate groups, while 
phosphatases (PPTases) work on removing these groups. Methyltransferases can 
interact with lysine or arginine residues by adding methyl groups (HKMT, histone 
lysine methyltransferases) (13) or PRMT, (protein arginine methyltransferases) and 
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histone demethylases such as JmjC and LSD1 catalyse the reversible process 
(14,15). 
In the biological context, histone tail modifications are involved in chromatin 
packaging activate or repress transcription depending on the modification and the 
residues that are modified. In general, acetylation is correlated with transcriptional 
activation (16), whereas methylation leads either to activation or repression. For 
example, an active gene promoter usually has trimethylation of lysine 4 on histone 
H3 (H3K4me3) (17), whereas marks such as trimethylation of H3K9 (H3K9me3) and 
H3K27 (H3K27me3)  are repressive marks correlated with transcriptional repression 
(11). 
3.4 Epigenetics and cancer 
There are several epigenetic characteristics that distinguish normal from cancer cells. 
These include global DNA methylation changes, histone modification patterns and 
chromatin-modifying enzyme expression profiles (18,19), which all have an influence 
on the initiation and progression of cancer. 
3.4.1 DNA methylation in cancer 
Changes in the CpG methylation status in the cancer epigenome include global 
hypomethylation of the cancer genome and local hypermethylation of CpG island 
promoters including tumor suppressor genes (8). Binding of chemical carcinogens 
and spreading of the UV-induced mutations are also increased by methylation of CpG 
sites (8). 
Repetitive sequences in cancer are usually hypomethylated, which leads to 
chromosomal instability such as translocations, gene disruption and reactivation of 
endoparasitic sequences (20,21).  Hypermethylation involves genes that are part of 
important cellular pathways such as DNA repair, cell cycle control and apoptosis 
(22,23). 
3.4.2 Histone modifications in cancer  
Alterations of histone modifications are also correlated with the cancer phenotype. 
HDACs are involved in the hypoacetylation process and have been found to be 
overexpressed (24) or mutated (19). An overall reduction of acetylation of H4K16 has 
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been reported for breast and liver cancer (25). There is also a global loss of the 
active H3K4me3 (26) and the repressive H4K20me3 mark (27)  and increased values 
of the repressive marks H3K9me3 (28) and H3K27me3 (29). These modifications 
attribute to aberrant expression of both histone methyltransferases such as EZH2 
and NSD1 (30,31) and histone demethylases such as GASC1, LSD1, JmjC and 
others(32-34).
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 Epigenetic alterations during oncogenesis. A DNA methylation alterations in cancer. In 
normal cells, CpG island promoters are generally unmethylated (white circles) and active, as in 
the case of tumor suppressor genes. An active gene shows an open chromatin structure with 
no nucleosome upstream of the transcription start site (black arrow). During tumorigenesis, 
tumor suppressor gene promoters with CpG islands become methylated (red circles) resulting 
in the formation of silent chromatin structure and aberrant silencing (red X on the black arrow). 
B In normal cells active tumor suppressor genes (black arrow) show an enrichment of active 
histone marks such as acetylation (yellow polygon) and K4 methylation (red rectangular) of 
histone H3. In cancer cells, gene silencing of tumor suppressors may occur through the 
enrichment of repressive histone marks like H3K27 methylation (green rectangular) mediated 
by the PRC complex and the removal of active histone marks (acetylation and H3K4 
methylation). C Abnormal miRNA expression in cancer. a Epigenetic changes like DNA 
methylation and histone medications are responsible for aberrant miRNA expression. For 
example, miR-124a is under epigenetic control in acute lymphoblastic leukemia (ALL) due to 
the fact that is embedded in CpG island regions that are silenced by hypermethylation. The 
result is that miR-124a is downregulated in ALL (when compared to normal cells) and its target 
CDK6 is up-regulated. b Epi-miRNAs are regulators of epigenetic effectors. For example, miR-
29 family targets DNMT3a and DNMT3b. In normal cells, the levels of miR-29 are increased 
leading to decreased expression of its targets (DNMT3a and DNMT3b), normal patterns of DNA 
methylation and expression of tumor suppressor genes. In lung cancer cells, miR-29 is down-
regulated resulting in up-regulation of DNMTs and hypermethylation and silencing of tumor 
suppressor genes 
From Epigenetic aberrations during oncogenesis- Maria Hatziapostolou • Dimitrios Iliopoulos
3.5 Anaplastic large cell lymphoma 
Anaplastic large cell lymphoma is classified into the group of T-cell non–Hodgkin 
Lymphomas (NHL). It was first identified in 1985 by Stein et al (35) as a large cell 
lymphoma with anaplastic cytology, uncommon growth sinus patterns, and high 
expression of the antigen CD30. 
In 80 % of cases (36), there is a translocation t (2;5), which was first described in the 
early 1990s by Morris and colleagues (37). It involves the receptor tyrosine kinase 
anaplastic lymphoma kinase (ALK) on 2p23 and nucleophosmin (NPM1) on 5q35. 
There are three distinct T-cell ALCL tumor classes: ALK positive ALCL, ALK negative 
ALCL (listed in the same category) and primary cutaneous (C-ALCL), which might be 
a different entity (38). The histology of ALK positive ALCL and ALK negative ALCL is 
quite similar. They form cohesive clusters of pleomorphic large cells with high mitosis 
rate and show the CD4+ and CD30+ phenotype (39). The large kidney shaped cells 
are “hallmark cells” for this type of tumor, although some of the ALK positive ALCL 
tumors can also contain small cells and lymphohistocystic variants (10-20% of cases 
from ALCL) (40). 
Diagnosis of ALK negative ALCL is featured on its strong expression of CD30 (41). 
Cutaneous ALCL, a CD4+ T-cell tumor, consists of large cohesive anaplastic cells 
with irregular nuclei that show similarity with those seen in systemic ALCL (42). 
Primary ALCL usually manifests during childhood. Current treatment of ALCL is 
based on the use of a combination of chemotherapy and CD30-agoninst antibodies 
such as SGN-30 (43). ALK positive ALCLs have a better treatment prognosis than 
ALK negative ALCL or other T-cell NHLs (44).  
3.5.1 ALK deregulation through the NPM-ALK fusion protein 
Anaplastic lymphoma kinase belongs to the transmembrane tyrosine receptor 
kinases (RTK) and is a member of the insulin receptor superfamily. It is activated by 
phosphorylation of its YXXXYY tyrosine motif. Autophosphorylation of this motif leads 
to a constitutively active NPM-ALK protein, which can cause oncogenic 
transformation of cells (45). 
The expression of the wild type ALK is usually limited to the central and peripheral 
nervous system and a role for midgut and neural tissue development has been 
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demonstrated (46-48).  
The ALK fusion partner NPM1 is a carrier protein involved in the transport of newly 
synthesized proteins between the cytoplasm and the nucleolus, in the regulation of 
cell division, in DNA repair, transcription and genomic stability (49). 
 3.5.2 NPM–ALK signaling pathways  
Signaling through NPM-ALK changes several cellular processes. The constitutive 
active kinase activates pathways such as: JAK/STAT, PI3-K/AKT, MAPK and PLCγ 
(50), leading to proliferation, prolonged tumor cell survival, cytoskeletal 
rearrangements and cell migration. 
JAK/STAT signaling contributes to regulatory functions of cytokins and controls 
processes such as cell growth, differentiation and survival. Phosphorylated JAK 
activates STATs and controls the mitogenic and antiapoptotic effects of ALK (51,52). 
STAT3 is phosphorylated and directly activated by JAK3 and its activation leads to 
translocation of STAT3 into the nucleus and increases the transcriptional levels of 
antiapoptotic molecules (53-58). STAT3 is also involved in the regulation of MYC, a 
potent oncogenic transcription factor, which is elevated in NPM-ALK transfected rat 
fibroblasts (59). Inhibition of STAT3 in ALK positive ALCL leads to apoptosis and cell 
cycle arrest (59). STAT5B is also activated by NPM-ALK via JAK2 and has a function 
in cell growth promotion (52,60), whereas STAT5A and SHP1 are epigenetically 
silenced via DNA methylation (61,62). 
The PI3-K/AKT pathway is involved in the regulation of several pathways such as the 
mTOR pathway, cyclin dependent kinase (CDK) inhibitors, p21 and p27, cyclin D, 
p53,  and  plays a role in different cellular processes like cell growth, and apoptosis 
(63). PI3-K/AKT also induces the Sonic Hedgehog signaling pathway (SHH). Sonic 
Hedgehog regulates T-cell differentiation, T-cell receptor repertoire selection, 
activation of the peripheral T-cell and inhibition of apoptosis in germinal center of the 
B-cells (50). Sonic Hedgehog is expressed in 100 % of the ALK positive ALCL and 
85% of ALK negative ALCL (64). It was suggested that inhibition of PI3-K/AKT/SHH 
pathway can increase the cell viability and can generate cell cycle arrest in ALK 
positive ALCL cell lines (64). 
The MAPK pathway activated by NPM-ALK is important for cell growth and 
differentiation. NPM-ALK has a role as docking molecule and activates the RAS-ERK 
14 
 
pathway thought docking different proteins such as insulin receptor substrate-1, SRC, 
SHC and PLC. Members of the ALK family such as stress activated protein 
kinase/C-JUN, N-terminal kinase and can be activated by environmental stress, 
inflammatory cytokines, and growth factors. They play a role in cell growth and 
survival, and have been also related to oncogenesis (50). 
The WNT/ß-catenin pathway is involved in regulating cell fate decisions during 
differentiation and development. Accumulation of ß-catenin in the cytoplasm and its 
translocation to the nucleus leads to binding and activation of members of the 
(TCF/LEF) family and upregulation of oncogenic proteins such as MYC and CYCLIN 
D1 (50). T-cell lymphoma such ALK positive and ALK negative ALCL are TCF-1/LEF1 
negative and a loss of PTEN expression (tumor suppressor–phosphatase and tumor 
homolog) is found in 66.7% of all ALCL cases (65,66). 
NOTCH is also involved in ALCL signaling and has a role in thymic maturation, 
peripheral T-cell proliferation and survival (67). Approximately 50% of T–ALLs have 
mutations in NOTCH and it was also found that NOTCH and Jagged (ligand of 
NOTCH) are highly expressed in ALK positive and ALK negative ALCLs (68). 
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Figure 2 Summary of NPM-ALK signaling network. Constitutive NPM-ALK signaling in 
anaplastic large cell lymphoma (ALCL) exerts its oncogenic effects via a complex network of 
redundant and interacting pathways. The MAPKs (ERK1/2 and JNK) have a central role in 
driving proliferation/survival via the induction of the AP-1 transcription factors and subsequent 
down-regulation of p21 (inhibitor of cell cycle progression), and upregulation of cyclin D3. Both 
ERK1/2 and PI3-K/AKT activate mTOR, which down-regulates the proapoptotic protein BAD 
and phosphorylates proteins p70S6K, S6RP, and EIF4E-BP1, thereby enabling messenger RNA 
translation and protein synthesis to proceed. The PI3-K/AKT pathway further enhances 
proliferation by increasing the expression of cyclin D2 via signaling through SHH and FOXO3A 
inhibition. FOXO3A inhibition also decreases the expression of the proapoptotic protein BIM 
and the negative cell cycle regulator p27. STAT3 is another major regulator of ALCL cell 
proliferation/survival via its upregulation of cyclins, MYC, C/EBPb, BCL2, MCL1, BCL-xL, and 
survivin. STAT3 signaling also promotes tumor growth/survival by stimulating the expression 
of the proangiogenic VEGF. STAT5B and the PLCg/PKC pathway are activated by NPM-ALK and 
promote cell proliferation/survival growth, although the downstream mediators are unclear. 
Finally, the anaplastic morphology of ALCL is a result of various cytoskeletal changes that may 
be mediated by signaling through GRB2/p130CAS/VAV and the RHO GTPases 
(RAC/RHO/CDC42).NPM-ALK is not drawn to scale. Abbreviations: ALK, anaplastic lymphoma 
kinase; AP-1, activator protein 1; BAD, BCL2 agonist of cell death; BCL2, B-cell lymphoma 2; 
BCL-xL, B-cell lymphoma-extra large; BIM, BCL2-like 11; C/EBPb, CCAAT/enhancer-binding 
protein b; EIF4E-BP1, eukaryotic translation initiation factor 4E–binding protein 1; ERK1/2, 
extracellular signal–regulated kinases 1/2; FOXO3A, forkhead box O3A; GRB2, growth factor 
receptor–bound protein 2; JAK2, Janus kinase 2; JAK3, Janus kinase 3; JNK, c-JUN N-terminal 
kinase; MAPKs, mitogen-activated protein kinases; MCL1, myeloid cell leukemia sequence 1; 
mTOR, mammalian target of rapamycin; MYC, myelocytomatosis oncogene; NPM, 
nucleophosmin; PI3-K, phosphatidylinositol-3 kinase; PKC, protein kinase C; PLCg, 
phospholipase C g; p70S6K, p70S6 kinase; p130CAS, p130CRKassociated substrate; SHC, 
SRC-homology-2-domain–containing transforming protein; SHH, sonic hedgehog; STAT3; 
signal transducer and activator of transcription 3; STAT5B; signal transducer and activator of 
transcription 5B; S6RP, S6 ribosomal protein; VEGF, vascular endothelial growth factor.  
From Anaplastic Large Cell Lymphoma -Kinney et al 
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3.5.3 ALK positive ALCL and Epigenetic Silencing 
Aberrant DNA methylation during oncogenesis contributes to malignant 
transformation. In ALCL aberrant promoter methylation has been detected for some 
candidate tumor suppressor genes such as p16 (INK4a), NFATC and SHP1 (69-71).  
Furthermore, it has been observed that STAT3 has an influence on epigenetic 
silencing, by inducing the expression of DNMT1. This leads to hypermethylation of 
SHP1 and thereby inhibits the ubiquitin-dependent degradation of NPM-ALK (71-73).  
The transcription factor NFATC is involved in the regulation of proliferation and 
proapoptotic effects. NFATC has been found to be silenced in lymphomas by 
hypermetylation of its promoter (69).  
Aside from this, a candidate gene approach looking at different commonly 
hypermethylated genes in cancer revealed high levels of methylation in ALCL cell 
lines and patient samples (Hassler et al. unpublished results). 
3.6 Epigenetic drugs and cancer therapy  
Epigenetic changes are reversible and this is used for developing effective anticancer 
therapy, as epigenetically silenced genes can be reactivated by treatment with DNA 
demethylation drugs and/or histone deacetylase inhibitors. DNA methylation inhibitors 
such as Aza and Zebularine or histone deacteylase inhibitors including SAHA 
(Suberoylanilide hydroxamic acid), valproic acid (VPA) and trichostatin A (TSA) show 
antitumor activity. Aza is FDA approved for treating myelodysplastic syndrome in 
patients (74-76). SAHA is approved for the treatment of cutaneous T-cell lymphoma 
(77). 
Nucleoside analogs such as Aza, which are DNA methyltransferase inhibitors, are 
incorporated into DNA forming covalent complexes with DNA methyltransferases (78-
80). These inhibitors are only incorporated when the cell is actively dividing, as it is 
the case for a cancer cell. The current idea is that the inhibitors reactivate silenced 
tumor suppressor genes. However if the dosage is too high, side effects such as 
cytotoxicity can occur (81). It was also shown that vessel formation, which is 
important for tumor formation, is decreased by using Aza and Zebularine (82). 
HDAC inhibitors are the second class of epigenetic drugs used for cancer therapy. 
They show anti-proliferative activity in cancer cells  probably by activation of the G2 
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checkpoint, which in normal cells leads to cell cycle arrest, while in cancer cells this 
pathway is defective (83). 
The HDAC inhibitor used for this study, MS-275, is a synthetic benzamide derivate, 
which has already been tested in clinical trials with patients with advanced solid 
tumors or lymphomas (84), where it could be shown that H3/H4 acetylation, p21 
expression and Caspase 3 activation were induced after treatment in bone marrow 
mononuclear cells, however, patients response was relatively poor (85). 
Furthermore, in preclinical studies, it was suggested that the combination of HDAC 
and DNMT inhibitors might show anti-tumor effects and re-expression of 
epigenetically silenced tumor suppressor genes (86). Studies were conducted in 
patients with advanced non small cell lung carcinoma (NSCLC). It was found that, the 
doses used were well tolerated and two of ten patients showed stable disease status. 
Therefore, the combination of the inhibitors might also be a possible treatment 
strategy to reactivate epigenetically silenced genes (86). 
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4. Material and Methods  
4.1 In vitro studies- Working with cell cultures 
Chemicals and reagents  
 5-Aza-2‟-deoxycytidine (Sigma-Aldrich) was dissolved in PBS (GIBCO) to a 
concentration of 100 mM. Then it was diluted to 1 mM and stored at -80°C.  
MS-275 was obtained from (Selleck Chemicals LLC) and diluted with DMSO (Sigma–
Aldrich) to a final concentration of 1mM and also stored at -80°C. 
 
Cell culture 
Mac-2A and Karpas-299 (ALK positive ALCL) and SR-786 (ALK negative ALCL) 
human cell lines were obtained from collaborators. Cells were grown in RPMI 1640 
medium (GIBCO) containing 10 % FBS (fetal bovine serum) and 1 % penicillin/ 
streptomycin. Cells were grown at 37°C in an atmosphere of 5 % CO2 and 95 % room 
air.  
Mac-2A, Karpas-299 and SR-786 were seeded in six well plates (BD Falcon™) at a 
density of 0.5 x 106 cells per ml in RPMI medium (2 ml). Four of the six wells were 
treated with 2 µl of 1 mM 5-aza-2'-deoxycytidine (final concentration 1 µM). Two wells 
were used as control and treated with 2 µl of PBS. 5-aza-2'-deoxycytidine was added 
only once at the beginning of the treatment.  
For MS-275 treatment, cells were seeded as described above and treated with 1 µl of 
1 mM MS-275 (final concentration 0.5 µM). It was added over a period of 4 days to 
each well/each day. Two control wells were treated with an equal volume of DMSO. 
1 ml of RPMI medium was added every second day to each well. Cells were counted 
using a C-Chip–disposable Hemocytometer (PeqLab). After 4 days of treatment with 
5-aza-2'-deoxycytidine and MS-275 the cells were centrifuged (for 4 min at 1400  
rpm), washed with PBS and the cell pellets were stored at -80°C.  
For confirmation, experiments were independently repeated two times.  
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4.2 In vivo studies-Working with Mice 
Tumor Xenografts studies  
The animal studies were performed using NOD.CB17-Prkdc^scid/NCrHsd 
(NOD/SCID, Harlan Laboratories) mice in collaboration with the Pharmacology 
Departmet of the Medical University of Vienna. All animal experiments were carried 
out in accordance with protocols approved by Austrian law. The mice were kept in a 
controlled environment of light, humidity and temperature. Food and water were 
provided every day. Karpas-299 (ALK positive ALCL) human cells were grown as 
described above, centrifuged, washed and dissolved in sterile PBS to a concentration 
of 1X107 cells/ml. The cells were inoculated subcutaneously (100 µl, 1x106 
cells/injection) into the right and left flanks of the mice.  
MS-275 was dissolved in 0.05 M HCL and 0.1% Tween and was given orally (p.o) in 
a concentration of 12 mg/kg/mouse.  
5-Aza-2'-deoxycytidine - DNA methyltransferase inhibitor was suspended in PBS and 
was supplied intraperitoneal (i.p) in a concentration of 2.5 mg/kg/mouse. 
Control mice were treated with 100 µl of sterile PBS. Tumor range was measured 
when the tumors were palpable and was calculated by the formula: tumor 
width*tumor length. The weight of the mice was approximately 25 g/mouse and was 
measured at the beginning of the therapy. 
Both therapies were adjusted regarding start and duration of the treatment in order to 
obtain optimal treatment procedures (Tables 1-3). 
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Table 1 
The therapy was started later because the tumors were ≤ 5 mm* 
Mice were 10 weeks old at the beginning of the therapy 
Table 2 
Mice were 6 weeks old at the beginning of the therapy 
 
Table 3 
Mice were 11 weeks old at the beginning of the therapy 
 
Xenograft 1 PBS control group of mice 
MS-275 treated group of                      
mice  
 Aza treated group of mice 
  
Number of mice  2 mice  
5 mice (treatment of one mouse   
was started 2 days after the treat.    
treat  
of the other four)* 
5 mice (treatment of one mice was  
started 2 days after the treatment of  
the other four)* 
How many days after cell  
inoculation did the therapy start?    
11 days 11 days 11 days 
Tumor range at the beginning of the  
therapy   
app. 1cm app. 1cm app. 1cm 
Tumor range first measured after 
cell inoculation/for how long  
11days after inoculation/  
measured 8 days/daily 
11days after inoculation/  
 
measured 8 days/daily  
11days after inoculation/  
 measured 8 days/daily  
How long was the treatment 
carried out? 
8 days/daily treatment 8 days/daily treatment 8 days/daily treatment 
How many mice died during the 
therapy? no dead mice  no dead mice  two mice 
Xenograft 2 PBS control group of mice  
MS-275 treated group of 
mice  
Aza treated group of 
mice 
  
 
Number of mice 
5 PBS mice (3 mice 5-aza (i.p) ; 2  
mice MS-275 (p.o) 
6 mice 6 mice  
How many days after cell 
inoculation did the therapy start? 
 
 
 
3 days 3 days 3 days 
Tumor range at the beginning of 
the therapy  
 
  
no palpable tumors  no palpable tumors  no palpable tumors  
Tumor range first measured after 
cell inoculation/for how long 
  
 
MS-275 control group: 7days/6days; 
Aza control group:7days/3days;  
   
 
7 days/6 
days 
7 days/3 
days 
How long was the treatment 
carried out?  
 
   
MS-275 and Aza control groups:Mo-
Fr; except weekends (MS-275:10 
times; Aza: 7 times of therapy) 
 
Mo-Fr; no therapy during 
weekends (10 times of therapy) 
 
 
Mo-Fr; no therapy during 
weekends (7 times of therapy) 
 
 
How many mice died during the 
therapy? 
 
no dead mice one mouse three mice 
Xenograft 3 PBS control group of mice 
Aza early treated group of 
mice 
 
 
Aza  late  treated group of 
mice 
 
 
Number of mice 3 mice  3 mice 4 mice 
How many days after cell 
inoculation did the therapy start? 
 
 
6 days 4 days 6 days 
Tumor range at the beginning of the 
therapy   
no palpable tumors  no palpable tumors  palpable tumors  
Tumor range first measured after 
cell inoculation/for how long 
 
 
6 days/4 times (every 2nd day) 6 days/4times (every 2nd day) 6 days/ 4times (every second day) 
How long was the treatment 
carried out? 
4 times every second day; no 
therapy during weekends  
 
 
5 times every second day; no 
therapy during weekends   
4 times every second day; no 
therapy during weekends   
How many mice died during the 
ttherapy ? no dead mice one mouse one mouse  
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 4.3 Cell Cycle Analysis by Propidium Iodide (PI) Staining  
 About 105 to 106 cells were suspended in 500 µl PI-buffer + RNAase (1:100) (Sigma) 
+ PI (1:50) (ROTH) and incubated for 30 min at 37˚C or 1 h at RT. 3 ml of PBS were 
added and cells were centrifuged at 1000 rpm for 5 min. The supernatant was 
removed. For flow analysis the cells were suspended in 500 ml PBS. The analysis 
was performed on a BD FACSCanto II flow cytometer using the BD FACS Diva 
Software. 
Flow analysis:  
Approximate settings (on FACS):  
FL1: 570 V log. (E.g.  to detect GFP)  
FL2: 470 V linear  
PI- buffer: 
0,1% Na-citrat (Na-citrat dihydrate p.a. 113,9 mg/100 ml) 
0,1% Triton X-100, for molecular biology (c=1,065 g/ml) 
0,1% Rnase (Ribonuclease), (DNAase free) 
Dilute in 1xPBS and filtrate through filter 0,2 um (sterile) 
For 100 ml Puffer: 
113,9 mg tri- Natriumcitrat dihydrate 
100 mg Triton X-100 
100 mg RNAse 
Dissolve in 100 ml 1xPBS, sterile filtrate (50 ml Falcon), store at 4°C. 
 
Propidiumiodide Stocksolution: 
Dissolve 1 mg/ml in PBS, filter sterile and store at 4°C. 
4.4 Work with DNA 
4.4.1 Isolation of genomic DNA 
This method was used for isolation of genomic DNA from cells and tissue. For 
isolation from tissues, the tissue was pulverized in liquid nitrogen. The pellet (from 
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cells or tissue) was dissolved in 500 µl genomic DNA isolation buffer. 20 µg/ml 
RNAase A was added to the mixture and incubated at 37°C for one hour. Then, 500 
µg/ml Proteinase K was added and the DNA was incubated o.n at 55°C. 
Phenol/chloroform extraction was performed in phase lock tubes. 1x Vol of phenol 
was added to the DNA mixture and the solution was centrifuged for 10 min at 13.000 
rpm at 4°C.The upper phase that contained the DNA was transferred to another tube 
and chloroform was added followed by centrifugation. The DNA was precipitated with 
1x Vol isopropanol and centrifuged as described above. The DNA pellet was washed 
with 1 ml of 75% ethanol and centrifuged again. The supernatant was carefully 
removed and the DNA pellet was dried at room temperature. The DNA was dissolved 
in sterile water and incubated at 37°C until completely dissolved. The DNA 
concentration was measured with a Nanodrop 2000 (Peqlab biotechnologies). 
Genomic DNA Isolation Buffer: 
0.4 M NaCl (5 M stock)  
0.2% SDS (10% stock) 
0.1 M Tris (1 M Tris pH 8.3) 
5 mM EDTA (0.5 M EDTA) 
4.4.2 Bisulfite Conversion and methylated DNA analysis by 
COBRA 
For bisulfite conversion the EZ DNA MethylationTM Kit (Zymo Research) was used 
according to the manufactuerer‟s protocol. 
The following program was used for o.n incubation in a thermocycler: (95°C for 30 
sec, 50°C for 60 min) x 16 cycles, then the temperature was reduced to 4°C.  
For PCR, 2 µl of the bisulfite converted DNA were used. The PCR product was 
analyzed on a 1.5-2% agarose gel. Primers for amplification of bisulfite converted 
DNA were designed using the SEQUENOM EpiDesigner program 
(http://www.epidesigner.com). 
For digestion, enzymes cutting the target sequence, containing CGs, were used 
(WNT2: HhaI (Fermentas); p16: TaqI (New England Bio Labs). As control fully 
methylated (SssI treated) and non-methylated (PBMC) DNA were used.  
15 µl of the PCR product in TAE were used for the digestion following the protocol 
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bellow. To analyze the methylation status, 15 µl of the restriction were loaded onto a 
10% Polyacrylamide Gel or onto an Agilent DNA chip (1000 series). 1 µl of the 
restriction product were used to obtain a virtual DNA gel (analysis program: 2100 
expert). Chip preparation was carried out according to protocol. 
 
PCR: 
2.5 l Buffer 
2.5 l MgCl2 
0.5 l dNTPs 
1 l (Primer fo+re) 
0.125 l Ampli Taq Gold Polymerase (Applied Biosynthesis) 
16.5 l H2O 
Restriction enzyme digestion: 
(15 µl PCR product)  
2 l Buffer 
0.5 l BSA 
0.5 l Res. Enzyme  
2 l H2o 
(or without BSA with 2.5 l H2O) 
10% Polyacrylamide Gel (40 ml): 
H2O-15.6 ml 
30% acrylamide mix–16 ml 
5x TBE–8 ml 
10% Ammonium persulfate (APS)–280 µl 
TEMED-14 µl 
4.4.3 Methylation-sensitive high resolution melting (MS-HRM) 
Preparation of control samples 
SssI treated DNA were used as methylation positive control and PBMCs as 
unmethylated negative control. A standard dilution series of 100% to 10%, 1% and 
0,1%  methylated DNA in a background of unmethylated DNA were prepared by 
serially diluting the methylated positive control into the unmethylated control. 
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Primer design for bisulfite PCR amplification 
Primer preparation: 
 Primer should have a length between 20- 40 nt 
 Include a limited number of CG nucleotides (1-3 nt) into the primer sequence 
at the 5' end. If it is not possible to include only few CGs, mismatch the C from 
CG with T 
 The correct melting temperature has to be checked out via qRT-PCR 
 Programs for calculating the correct annealing temperature: 
http://www.promega.com/biomath/calc11.htm     
https://www.finnzymes.fi/tm_determination.html 
 
Primer sequence used for the analysis: 
p16HRMfo: GGAGTTTTCGGTTGATTGGTTGGTT(25) 
p16HRMre:  AACAACGCCCGCACCTCCTCTA(22)  
PCR reaction mixture: 
(preparing a mastermix by adding the following reagents to 2 μl of DNA) 
10 μl  KAPA SYBR FAST qPCR Mastermix (2x) 
  1 μl   Primer  
  7 μl  H2O 
 20 μl  total 
4.5 Work with Proteins  
4.5.1 Western Blot/Protein Extraction  
From tissue 
Tumor tissue was put into a dounce homogenizer. 500 µl Hunt buffer and 5 µl 
protease (c=10 mg/ml) (Roche) and phosphatase inhibitor (Phosphatase Inhibitor 
Cocktail Tablets-Roche) were added. The tissue was dounced 10-15 times until well 
dissolved. The homogenate was frozen in liquid nitrogen and then put on ice to thaw.  
From cells 
The pellet was dissolved in 100-200 µl Hunt buffer with previously added protease 
and phosphatase inhibitor. The pellet was frozen in liquid nitrogen, put at 37°C to 
thaw, then frozen again and put on ice until completely thawed. 
Then the solution (from tissue or cells) was centrifuged for 10 min at 4°C, the 
supernatant was taken out and the protein concentration was measured using 
Coomassie Plus Protein Assay Reagent (Pierce) diluted with H2O (1:1) and the 
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protein concentration was measured with a spectrophotometer (HITACHI) or 
Nanodrop 2000 (Peqlab biotechnologies). Samples were diluted with protein loading 
dye-2xSDS gel-loading dye (1:1), heated for 5 min at 95°C and loaded onto an 
already prepared SDS-PAGE (5-15%) gradient gel  (50 µg of protein per lane). 
2xSDS gel-loading dye, reduced: 
100 mM Tris-HCl pH 6.8 
200 mM DTT 
4% SDS 
20% Glycerin 
Bromphenolblau (up to 20 ml) 
Reduced gel loading dyes protonated and should be stored at -80°C. 
 
Western Blot 
The gel was transferred onto a nitrocellulose membrane (wet o.n transfer at 25V). 
The membrane was stained with Ponceau Red and washed with TBS-T. It was 
blocked with Blocking solution and incubated with primary antibody o.n. It was 
washed again with TBS-T (3x5 min) and incubated with secondary antibody for one 
hour. The membrane was incubated with chemoluminiscent solution ECL plus (GE 
Healthcare-1:40 diluted) and the signal was detected with the Lumi Analyst (Roche 
Applied Science). 
 
Hunt Buffer: 
20 mM Tris pH 8 
100 mM NaCl 
1 mM EDTA 
0.5% NP-40 (stock 10%, fresh) 
Protease inhibitor-Complete (Roche)  
10X TBS (1l): 
60.5 g Tris Base 
90 g NaCl  
With HCl to pH 7.5 
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TBS-T:  
1x TBS 
0.1% Tween 
 
Blocking Solution: 
 
10 g (5%) milk powder 
400 µl Na-Azid (10%) 
Fill up with TBS-T to 200 ml 
4.5.2 Isolation of Core Histones 
Tumor tissues were pulverized with liquid nitrogen. 1 ml Nuclear Isolation Buffer and 
20 µl protease inhibitor (c=10 mg/ml) were added and the solution was centrifuged 
for 5 min, 500xg at 4°C. The supernatant was discarded and 100 µl of 0.4N H2SO4 
were added to each tube. Afterwards, the tubes were put on ice for one hour. The 
solution was centrifuged for 5 min, 7500 rpm, at 4°C. The acid soluble supernatant 
was collected in 2 ml eppendorf tubes and precipitated with 10x Vol ice-cold acetone. 
The proteins were precipitated at -20°C o.n. Then they were centrifuged for 10 min, 
max speed, at 4°C. The supernatant was discarded and the pellets were washed with 
500 µl acetone. Then, it was centrifuged again and the supernatant was discarded. 
The pellets were dried at room temperature and resuspended in 200 µl sterile water. 
The protein concentration was measured using the Nanodrop 2000 (Peqlab 
biotechnologies). Histones were stored at -80°C until usage. 
Nuclear Isolation Buffer: 
10 mM Hepes pH 7.4 
150 mM NaCl  
1.5 mM MgCl2 
0.5% NP-40 
4.6 Immunhistochemistry  
The paraffin slides were put at 56°C o.n. For deparaffinization the slides were 
washed three times for 10 min in xylol, then rinsed in 100% (three times), 70%, and 
50% EtOH and washed two times with distilled water. For antigen retrieval, the slides 
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were put into citrate buffer (pH 6) and heated in the autoclave. After cooling down at 
RT for 30-45 min, the slides were washed 3 times with PBS. To block endogenous 
peroxidase, the slides were washed with 3% H2O2 (Gatt-Koller) for 10 min and then 3 
times with PBS. The staining area was marked with a PAP pen (Sigma-Aldrich). 
Then, the slides were blocked with Avidin Block (Zamponi Diagnostik) for 10 min and 
washed again 3 times with PBS. Biotin Block was added for 10 min followed by 3 
times PBS washing. Then, the slides were blocked with Super Block for max. 7 min 
and washed 3 times. The slides were incubated with primary Antibody diluted in 1% 
PBS/BSA o.n at 4°C. Slides were washed 5 times and incubated with secondary 
antibody (anti-polyvalent biotinylated antibody) for 10 min. After washing 3 times the 
slides were incubated for 10 min with Streptavidin HRP (streptavidin peroxidase). 
Slides were stained with AEC (ID-Labs) and observed under the microscope to 
achieve optimal staining results and then stopped with distilled water. The slides were 
put in haemalaun solution (Merck) for 30 sec and washed with water. To complete the 
procedure the slides were mounted using aquatex (Merck) and cover glasses. 
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4.7 Antibodies  
Antibodies used for Western blot 
 
 
Antibodies used for Immunhistochemistry 
Antibody Dilution WB Company
Ki 67 1/1000 Cell Signaling
Caspase 3 1/200 Cell Signaling  
 
H&E staining was performed by the Clinical Pathology-Immunhistochemistry 
department at the Vienna‟s General Hospital. 
 
 
 
 
 
 
Antibody  Dilution WB  2nd antibody  Company  
Dnmt1 goat polyclonal   1/1000 goat Santa Cruz 
HDAC1  1/1000 mouse Seiser laboratory 
HDAC2 1/1000 mouse Seiser laboratory 
HDAC3 1/1000 mouse Seiser laboratory 
ß-Actin 1/1000 rabbit Cell Signaling 
NPM1 1/1000 mouse 
obtained from Hematopathology 
3J  
NPM-ALK 1/1000 mouse 
obtained from Hematopathology 
3J  
p-STAT3 ( Tyr 705) 1/1000 and 1/5000 rabbit Cell Signaling 
p-Erk 1/1000 rabbit Cell Signaling 
Erk total  1/1000 rabbit Cell Signaling 
H4 global  1/1000 rabbit Cell Signaling 
Ac H3(K9) 1/1000 rabbit Cell Signaling 
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5. Results 
We were interested in studying the effects of two different types of epigenetic drugs 
on ALCL in vitro and in vivo. Our research was centered on the following objectives:  
1) To analyze the effect of the inhibitors on cell proliferation in vitro. 
2) To perform an in vivo study using a Xenograft model. 
3) To analyze the in vivo effects of the drugs (DNA methylation status of candidate 
genes, depletion of DNMT1 after Aza treatment, hyperacetylation of histones after 
MS-275 treatment). 
5.1 In vitro and in vivo analysis after treatment with Aza 
5.1.1 Effects of Aza on ALK positive ALCL and ALK negative 
ALCL cell lines 
To evaluate the effects of Aza we performed in vitro studies with ALK positive ALCL 
and ALK negative ALCL cell lines. We have used two ALK positive (Karpas-299 and 
SR-786) and one ALK negative (Mac-2A) cell lines. Aza was administered once at 
the beginning of the treatment. In the Aza treated cells after 4 days of treatment the 
number of treated cells was reduced to around 55% less Mac-2A and SR-786 cells 
and 36% less Karpas-299 cells compared to PBS treated cells (Figure 3). In 
conclusion all treated cell lines were highly sensitive to Aza treatment. 
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Figure 3 Treatment of ALK positive ALCL (Karpas-299 and SR-786) and ALK negative (Mac-2A) 
ALCL cell lines with Aza. Cells were treated for 4 days with 2 µl of 1 mM Aza (c=1 µM). Controls 
were treated with 2 µL of sterile PBS. 
 
5.1.2 Effects of Aza in a Xenograft model  
Encouraged from our in vitro studies we performed in vivo-Xenografts using 
NOD/SCID-mice. ALK positive ALCL cells (Karpas-299) were inoculated into the 
mice. The mice were kept and treated as described in material and methods. In the 
first Xenograft the therapy was started 11 days after tumor cell inoculation, when 
palpable tumors were observed. Aza treatment did not achieve our expectations, 
because the tumors were aggressive and in advanced stage, when the treatment 
was started (more information about treatment and duration see Table 1). The mice 
involved in the next Xenograft were treated 3 days after tumor cell inoculation and did 
not have palpable tumors at the beginning of the therapy. This treatment schedule 
was very effective and was able to stop tumor growth in most of the treated mice 
compared to non-treated control mice, however with cytotoxic side effects (for more 
information about treatment and duration see Table 2). In order to obtain tumor 
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material for histological and molecular analyses we performed another Xenograft 
model with a different treatment schedule. The first group Aza early was treated 4 
days after tumor cell inoculation and had no palpable tumors at the beginning of the 
treatment. The second group Aza late had palpable tumors at the beginning of the 
treatment and was treated 6 days after inoculation. The last group was the PBS 
control group where the PBS implementation started at the same time with the Aza 
late group. The Aza early was treated 5 times every second day (no treatment during 
weekends), whereas the Aza late and PBS control group was treated one time less, 4 
times, every second day (no treatment during weekends) (for more information about 
treatment and duration see Table 3). This Xenograft showed reduced tumor growth 
and weight in treated compared to untreated mice, less cytotoxicity and we could 
obtain valuable tumor material for our following investigations. The figures below 
refer to the last Xenograft model (see also supplementary tables S1-S6 and 
supplementary figures S1 and S5 for more details about Aza-Xenograft treatments). 
The tumors of Aza treated mice were smaller in size and weight compared with the 
non-treated controls (Figure 4). 
 
Figure 4 Tumor photograph from mice. (a) Aza early treated mouse (b) PBS-control mouse  
 
Aza treated tumors showed significant size and weight reduction compared to the 
non-treated controls (Figure 5,6).  
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Figure 5 Treatment of mice with Aza. The tumor range (length*weight) was calculated as 
average of all tumor ranges. The tumor range was first measured 6 days after cell inoculation.  
(see also Table.3-Material and Methods for additional information).                             
 
 
 
 
 
 
 
 
 
Figure 6 Tumor weight of Aza treated vs. non-treated mice. After Aza therapy mice were 
sacrificed and the tumors (n(Aza early)=2; n(Aza late)=5; n(PBS control)=5) were isolated and 
measured. The figure shows tumor weight average of all three groups of mice. Tumor weight is 
reduced in the treated compared with the non-treated group. 
To conclude, tumor growth and tumor weight reduction was observed in the both 
treated groups, whereas the non-treated group showed increased tumor growth and 
tumor weight. 
5.1.3 FACS analysis of Aza treated mice  
To analyze the effect of Aza on proliferation we isolated cells from the tumor tissue 
and performed FACS analysis.  First, our results demonstrated that there are more 
cells in the G1 phase in treated compared with the non-treated mice (Figure 7a). 
Untreated tumors proliferate to a highly extend and more tumor cells are present in 
the S-phase from the non-treated then the treated mice (Figure 7b). Sub G1 phase 
showed an increased number of apoptotic cells present in the treated compared with 
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the non-treated tumors from control mice (Figure 7c) (see also supplementary figure 
S2 for FACS analyses from the first Xenograft treatment). 
 
 
Figure 7 FACS analyses of Xenograft tumors (a) An increased number of cells is observed in 
the G1 Phase. (b)The S-phase shows increased number of dividing cells in tumors (PBS) 
compared with Aza treated mice. (c) Sub G1 shows more nuclei of apoptotic cells in treated 
then in untreated mice. Aza early group of mice was treated two days earlier then the Aza late 
group (see Table 3). 
 
Therefore, our data show that Aza treatment reduces the proliferation of tumor cells 
and causes increased apoptosis.  
5.1.4 DNA methylation status of tumor suppressor genes 
The cancer genome has an altered epigenetic landscape. Several tumor suppressor 
genes such as p16 or, RASSF1A show changes in epigenetic patterns and sustain 
epigenetic silencing (87-89). We performed DNA methylation analysis using bisulfite 
converted DNA isolated from the Xenografts of untreated and Aza treated mice to 
analyze the methylation status of candidate tumor suppressor genes usually silenced 
in ALCL. It has been shown that WNT2 is hypermetylated in ALCL cell lines 
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(M.Hassler, personal communication). We confirmed, that WNT2 is less methylated 
in mice after treatment with Aza compared to the non-treated control group (Fig. 8).  
 
Figure 8 COBRA analysis of WNT2. Analysis of the methylation status of bisulfite converted 
DNA of the WNT2 promoter. The non-treated group (control) showed higher methylation levels 
compared with the treated groups (early and late treated) as seen by a higher intensity of the 
undigested band representing unmethylated DNA. Unmethylated-PBMCs (un.met) and 
methylated-SSSI treated DNA (met) were used to indicate non-methylated and completely 
methylated samples. 
 
We have also confirmed the methylation status of WNT2 using the Agilent DNA-Chip 
1000, which is a more sensitive method for detection of the methylation status of 
candidate genes. In the figure below the reduction of the methylation status in the 
treated mice, but not in the controls, was confirmed (Figure 9a).  
In the electropherogram we have compared the peaks of the unmethylated DNA with 
the controls and the treated mice. It was observed that the peak seen at 80 seconds, 
which represents the unmethylated PCR product, is also present in the Aza treated 
mice, whereas in controls this peak is very low. This also confirms that the 
methylation status of WNT2 is lower after Aza treatment (Figure 9b). 
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a. 
 
 
b. 
 
 
 
 
 
 
 
Figure 9 DNA methylation analyses. (a) DNA methylation analysis of WNT2 using DNA Chip-
1000. The methylation status of the treated (aza early, aza late) was decreased as compared to 
non-treated (control) groups of mice. As controls methylated (SSSI treated) and unmethylated 
(bisulfite treated-PBMCs) DNA were used. (b) Electropherogram of WNT2 using DNA Chip 
analysis. The peak seen at 80 seconds, which represents the unmethylated product, is higher 
in treated mice, whereas in the methylated control sample there is a higher peak between 60 
and 80 seconds, representing the non-methylated product, which is also observed in the non-
treated controls. 
 
Furthermore, the methylation status of p16, a tumor suppressor gene, which is found 
to be hypermethylated in diverse cancers such as multiple myeloma, T-cell 
lymphomas and colorectal cancer and which is also associated with lymphocytic and 
plasmacytic malignancies (70,88-90), was analyzed using methylation-sensitive high 
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resolution melting (MS-HRM). Standards with different methylation levels were used. 
100% methylated (SssI treated bisulfite DNA) was diluted to 10%, 1% 0,1% 
standards (see Materials and Methods). T-cells (bisulfite treated PBMCs) were used 
as unmethylated control. We have used DNA samples from the two Aza treated 
groups Aza early and Aza late, and from the untreated PBS control group of mice. 
Untreated control mice (82L, 76L, 51L) have higher p16 methylation patterns 
compared with the treated group. Reduction in methylation patterns was also 
observed in the Aza late group (77L, 77R, 81R) compared with non-treated control 
group, but the methylation level was increased compared with the Aza early treated 
group (79L, 78L), which had the lowest methylation patterns in these three groups. 
 
Figure 10 Melting curve analysis of p16. The figure shows differences in the methylation status 
between the two treated groups mouse Aza early: (79L, 78L) and Aza late: (77L, 77R, 81R) and 
non-treated: (82L, 76L, 51L) mice. Standards (black curves) diluted from 100% to 10%, 1% and 
0,1% and also unmethylated (0%) were used to compare and confirm the methylation patterns 
of p16. Methylation patterns are increased in non-treated compared with Aza late and Aza early, 
where less methylation is observed. 
 
In conclusion, DNA metyhtransferase inhibitors can decrease hypermethylation levels 
of epigenetically regulated target genes in vivo in an ALCL Xenograft mouse model.  
5.1.5 Protein analysis of Aza treated Xenografts 
DNMT1 is a maintenance methyltransferase involved in copying the methylation 
pattern from the mother to the daughter cell. DNMT1 is covalently bound to DNA after 
Aza treatment and therefore depleted from the protein extract. Furthermore, it was 
suggested that DNMT1 might undergo proteosomal degradation after treatment with 
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Aza (91). Our analyses have also shown that there was no DNMT1 protein present 
after Aza treatment compared with the control group where DNMT1 protein was 
highly abundant in the protein extracts (Figure 11).  
 
           
 
                
 
 
Figure 11 DNMT1 expression in mice treated with Aza. After treatment with Aza there was no 
Dnmt1 detectable in treated mice (Aza early, Aza late) compared with untreated control mice 
(Control). ß-Actin is used as loading control. 
 
These data indicate that Aza efficiently depleted DNMT1 in vivo in the tumor cells of 
the Xenograft (DNMT1 depletion was also observed after the first Xenograft 
treatment see supplementary figure S3). 
5.1.6 Immunohistochemistry staining of Aza treated tumor 
tissues 
In order to observe histological changes in Aza treated Xenograft tumors we 
performed immunohistochemistry staining. Observations regarding histology were 
treated mice made after staining with hematoxylin and eosin. We have observed 
more apoptotic areas in mice treated with Aza compared with untreated controls 
(Figure 12). Caspase 3 staining was performed to identify apoptotic areas in the 
tumors. As expected from H&E staining, Caspase 3 was highly expressed in treated 
mice (Figure 12). Ki-67, which is expressed in dividing cells, was used as a cellular 
marker for proliferation. The cells in untreated mice had a higher proliferation rate 
then the cells in treated mice (Figure 12) (supplementary figures S4 and S6 for more 
information about the Immunohistochemistry staining after the first two Aza 
treatments). 
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Figure 12 Immunohistochemistry staining of paraffin embedded tumor tissue sections in mice 
after treatment with Aza (early or late treatment). (C; D) are sections of two treated mice (early 
and late treated) compared with (A; B) sections of two non-treated mice. H&E staining showed 
increased apoptosis rates in treated (1C, 1D) compared with non-treated (1A, 1B). Ki-67 
staining showed higher proliferation in non treated (2A, 2B) vs. treated (2C, 2D).  Caspase 3 
was higher expressed in treated mice (3C, 3D) compared with non treated mice (3A, 3B).  
 
To conclude, it was observed that Aza treated mice showed increased apoptosis and 
Caspase 3 activity and decreased proliferation rates. 
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5.2 In vitro and in vivo analysis after treatment with MS-275 
5.2.1 Effects of MS-275 on ALK positive ALCL and ALK 
negative ALCL cell lines 
To evaluate the effects of MS-275 we also performed in vitro studies with ALK 
positive ALCL and ALK negative ALCL cell lines. The same tumor cell lines as 
described above (see Aza treatment) were used and MS-275 was administrated 
daily. 
Reduced cell number was observed in MS-275 treated cells after 3 days of treatment; 
around 35% reduction in Karpas-299 and Mac-2A, whereas SR-786 cell number was 
reduced to 57% (Figure 13). Thus, ALCL cell lines were not just highly sensitive to 
Aza, but also to MS-275 treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13 ALK positive (Karpas-299 and SR-786) and ALK negative (Mac-2A) cell lines with MS-
275. Cells were treated for 3 days with 1 µl of 1 mM MS-275 (c=0.5 µM). Controls were treated 
with 1 µl of DMSO. 
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5.2.2 In vitro protein analysis of MS-275 treated cell lines 
We tested the NPM-ALK protein levels in vitro in cells treated with MS-275. ALK 
positive ALCL (Karpas-299 and SR-786) and ALK negative ALCL (Mac-2A) protein 
extracts were used. We observed decreased levels of NPM-ALK in the two ALK 
positive cell lines after 3 days of daily treatment with MS-275. The expression levels 
of NPM1 were slightly reduced after treatment in all three cell lines. There was no 
NPM1 protein detectable in PBMCs (Figure 14). 
 
                   
 
 
 
 
 
 
 
 
Figure 14 In vitro analyses. Protein expression profiles of NPM-ALK and NPM1 after 3 days of 
treatment with MS-275. NPM1 is expressed in treated and untreated (DMSO) protein extracts, 
whereas NPM-ALK is less expressed in treated ALK positive ALCL cell lines (Karpas-299 and 
SR-786). 
Our data suggest that treatment with MS-275 leads to a reduction in NPM-ALK 
protein levels. It will be interesting to analyze in the future whether this is a 
transcriptional effect or due to increased proteosomal degradation. 
5.2.3 In vivo analysis of Xenograft mice treated with MS-275 
To analyze the effectiveness of MS-275 treatment in vivo we also performed 
Xenografts in mice. In the first Xenogarft the MS-275 therapy started 11 days after 
tumor cell inoculation at the time the tumors were palpable and aggressive. In the 
second Xenograft model the treatment started 3 days after tumor cell inoculation, 
where no palpable tumors at the beginning of the treatment were observed. Even 
though the two Xenografts showed slightly reduced tumor growth in treated mice, 
there was no visible difference in tumor weight between the treated and non-treated 
group of mice (Figure 15). The following figures refer to the first Xenograft treatment 
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(see also Table 1) and are comparable to the second set of Xenografts (data not 
shown).  
 a.                                                                  b. 
 
 
 
 
 
 
Figure 15 Tumor growth and weight in MS-275 treated compared with untreated mice. (a) Tumor 
growth reduction is observed in treated mice. (b) There is no difference in tumor weight in both 
groups: n(treated)=6, n(control)=4.  
5.2.4 FACS analysis of MS-275 treated mice 
Next we performed FACS analysis to analyze the cell cycle profile after MS-275 
treatment. We observed a slight increase in G1 phase and a decrease in S-phase in 
MS-275 treated tumor cells compared to non-treated cells (Figure 15). Interestingly, 
we detected an increase in Sub G1 cells in control tumors, which might indicate an 
increased apoptosis due to the large size of the tumors. Thus, our data suggest that 
MS-275 treatment showed a slight effect on proliferation of Xenograft tumors. The 
effects observed were not significant and might be due to instability or bad uptake of 
the drug in vivo.    
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Figure 16 FACS analysis of MS-275 treated Xenografts. In G1-phase there is an increased 
number of cells of MS-275 treated mice compared with non-treated (PBS) control. In S-phase 
there are more dividing cells in tumors from untreated mice. Sub G1-phase shows fewer 
apoptotic cells in treated then in the control group.  
5.2.5 Protein analysis of MS-275 treated Xenografts 
Protein analyses were performed to analyze the acetylation patterns after the 
treatment with MS-275. We detected increased acetylation of hostone H4 in treated 
mice. As a loading control we used an antibody against global histone H3 (Figure 
17). In summary our data show effects of the drug on global histone acetylation, 
although no significant changes in tumor growth or apoptosis could be detected.  
 
 
 
 
 
 
 
Figure 17 Analysis of histone acetylation levels in MS-275 treated mice. Increased acetylation 
can be observed in the treated mice compared with the non-treated PBS control group. The 
global H3 was used as loading control. 
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5.2.6 Immunohistochemistry staining of MS-275 treated mice 
tissues 
To monitor the effects of MS-275 therapy we have also performed immunohistological 
staining using the same markers as above. Proliferation was slightly decreased in the 
treated mice (2C, 2D) as analyzed by Ki-67 staining. Apoptotic areas were detectable 
in both untreated and treated tumors as analyzed by Caspase 3 staining (3A-D) and 
most likely not an effect of the drug treatment but rather increased tumor size and 
bad nutrient supply of the tumor cells. We conclude that further experiments with 
different doses and schedules of MS-275 treatment will be necessary to demonstrate 
the efficacy of the drug in vivo.  
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Figure 18 Immunohistochemistry Staining from MS-275 treated tumor tissues. Apoptosis areas 
observed in treated and non-treated mice (1A-D). There is a slightly lower proliferation rate in 
treated (2C, 2D), then in untreated mice (2A, 2B). Caspase 3 appeared higher in treated (3C, 3D), 
compared with untreated mice (3A, 3B). 
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6. Discussion 
In our study, we aimed to analyze the effects of DNMT and HDAC inhibitors on ALCL 
cells in vitro and in vivo.  
Hypermethylation of CpG islands in the cancer genome was described in the early 
nineteen‟s in a retinoblastoma model (92,93). It has been shown that decreasing of 5-
methylcytosine in hypermethylated CpG islands in cancer is associated with lowering 
the number of the tumors (94).  
Nowadays, epigenetic therapy is tested for treating diseases with epigenetic etiology 
such as different cancers. This therapy aims at reactivating silenced tumor 
suppressor genes. Aza showed promising results in various clinical trials (95-97). 
Clinical trials for the treatment of melanoma approved the effectiveness of Aza as 
demethylation agent, although the authors recommend prolonged low dose exposure 
in order to prevent cytotoxicity (98,99). Aza is also approved from the FDA for treating 
myelodysplastic syndromes (MDSs) in patients (97). 
Encouraged from our in vitro studies with three different ALCL cell lines we 
implemented a Xenograft model using the ALK positive Karpas-299 cell line. We 
confirmed that tumor size and weight are decreased after treatment with Aza. We 
studied the methylation pattern of epigenetically silenced tumor suppressor genes. In 
line with previous studies that have shown demethylation of DNA after using this drug 
(100), we have also observed, a decrease in methylation patterns after Aza treatment 
in hypermetylated tumor suppressor genes, such as p16 and WNT2. 
The tumor suppressor gene p16, located at chromosome 9p21, regulates the cell 
cycle with a functional unit constituting of p16, cyclin D1 and pRb. Early studies 
showed that p16 methylation in diverse myeloma decreases after treatment with Aza 
(90). Methylation of p16 has been detected in several lymphocytic and plasmacytic 
malignancies such as lymphoma, acute lymphocytic leukemia and multiple myeloma 
and shows a relation to the pathogenesis of these diseases. Demethylating agents 
such as Aza that revert p16 methylation are promising drugs for future therapy for 
treating such diseases (88). 
Recent studies showed that NPM-ALK is involved in inducing DNA damage and 
irreversibly arresting the cell cycle (101). In the tumor development this process is 
called oncogene induced senescence and is related with activation of the ARF/p53 
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pathway, which is widely inhibited in lymphomas and leukemias. NPM–ALK 
lymphomagenesis showed p16 dependent accumulation of senescent cells in pre-
malignant lesions and also lowering of the tumor latency in absence of p16 could be 
observed (101). However, we know that p16 is silenced in ALCL and its reactivation 
with upregulating either the histone demethylase-Jmjd3 or using demethylating 
agents could be a new strategy to reset the senescence program in tumors (101). 
In our study we observed decreased methylation of the WNT2 promoter after 
treatment with Aza. From the literature it is known that WNT2 regulates diverse 
pathways and aberrant expression is associated with different types of cancer. In 
parathyroid carcinoma there is a defect in the WNT2/β-catenin pathway caused by 
DNA methylation in APC and in vitro treatment with Aza induced APC expression, 
reduced active nonphosprorilated β-catenin, inhibited cell growth, and apoptosis 
(102). 
Genexpression is regulated through the action of DNA methyltransferases. It was 
reported that DNMT1 expression levels are induced and regulated upon entry into 
the S-phase of the cell cycle, and its over expression is probably not responsible for 
the aberrant methylation in cancer cells (103). In our study we found depletion of the 
DNMT1 in Aza treated mice. Other studies reported that DNMT1 is overexpressed in 
gliomas (104), whereas DNMT3b, but not DNMT1 is over expressed in prostate 
cancer (105). Treatment with DNA methyltransferase inhibitors reduced the enzyme 
levels and caused re-expression of silenced tumor suppressor genes (104,105).  
On the other hand, NPM–ALK is the most prominent fusion protein in ALCL and it 
downregulates T-cell receptor signaling molecules by STAT3 mediated gene 
transcription or epigenetic silencing, which is reverted by treating ALCL with Aza 
(106). It has been observed that in NPM–ALK positive cell lines STAT5A expression 
is inhibited directly by NPM-ALK induced methylation via STAT3. The same study 
also showed that treatment with Aza reactivates the gene (107).  Another study 
suggested that NPM-ALK downregulates T-cell receptor signaling molecules by 
STAT3 mediated gene transcription or epigenetic silencing, which is reverted by 
treating ALCL with Aza (106). SHIP is also epigenetically regulated and silenced in 
ALCL and treatment with Aza in Karpas-299 cell line reactivates its expression in over 
5 days (62). 
MS-275 has been investigated in patients with acute leukemias, mostly AML. In 
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treated patients increased levels of p21 and Caspase 3 activity were observed (108). 
MS-275 is currently in the clinical Phase I for treatment of advanced leukemia and 
MDS (85).  Clinical studies observed the effects of HDAC inhibitors on T-cell 
lymphoma, Hodgkin lymphoma, and myeloid malignancies and conclude that these 
drugs induce hyperacetylation and can be well tolerated from patients (109). Our 
results did also confirm slightly elevated acetylation upon usage of MS-275 in mouse 
xenograft tumors. In addition, our immunhistochemistry tissue staining indicated 
slightly higher Caspase 3 activity in treated and slightly increased proliferation in non-
treated mice. In general, MS-275 treatment did only show limited inhibition of tumor 
growth and no weight reduction of tumors in most of the treated mice. The reasons 
for this could be not optimized dose of MS-275 or bad uptake of the drug. In vitro we 
showed that the cell number is reduced in all MS-275 treated cell lines and reduction 
of the NPM-ALK expression levels after treatment with MS-275 in the ALK positive 
cell lines. Further studies have to be done in order to improve the effectiveness of 
this drug in ALCL in dose/survival depended manner and also investigation on 
metabolic pathway and uptake of MS-275.  
Many studies reviewed the effects of epigenetic drugs and combination therapy 
(HDAC and DNMT inhibitors) and their efficacy for treatment of cancer (110,111). 
Future approaches in this field might include both genetic therapy, which includes: 
small-molecule inhibitors of oncogenic signals, antibodies to surface components and 
intercellular communicating factors, and molecularly defined vaccines (112) and 
epigenetic therapy (113)  for successful treatment of cancer. 
In conclusion, epigenetic therapy showed promising results for the treatment of ALCL 
in mice and the future perspectives in this field should focus on adapting epigenetic 
therapy that can be effectively used and well tolerated by cancer patients.  
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7. Supplementary  
7.1 Aza treatment 
7.1.1 Xenograft 1 
   
Table S1 Tumor growth measurement during Aza treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table S2 Tumor weight measurement after Aza treatment. 
 
 
 
 
Aza
Day 1 Day 3
No Tu Length Width Circ. Tu Length Width Circ. Tu Length Width Circ. Tu Length Width Circ.
140 R 0,95 1,3 1,24      1 1,4 1,40      1,2 1,75 2,10      1,25 1,8 2,25      
140 L 1,1 0,9 0,99      1,3 1,1 1,43      1,5 1,3 1,95      1,35 1,2 1,62      
143 R 0,95 0,75 0,71      0,9 0,9 0,81      1,05 0,9 0,95      1 1 1,00      
143 L 0,65 0,9 0,59      1,1 0,85 0,94      1,1 1,05 1,16      1,1 1,2 1,32      
144/145 R 0,75 0,7 0,53      1,1 0,9 0,99      1,3 0,9 1,17      1,2 1 1,20      
144/145 L 0,8 0,7 0,56      0,9 0,8 0,72      1 1 1,00      1,15 1,1 1,27      
147 R 1,05 0,85 0,89      1,2 1,1 1,32      
147 L 0,7 1 0,70      0,85 0,75 0,64      
156 R 0,6 0,5 0,30      0,6 0,6 0,36      0,6 0,6 0,36      0,7 0,55 0,39      
156 L 1 0,9 0,90      0,95 0,95 0,90      1,5 0,8 1,20      1,5 1,25 1,88      
MITTELWERT 0,74      0,95      1,24      1,36      
148 R 1,1 0,75 0,83      1,1 0,9 0,99      1,3 1,1 1,43      1,4 1,5 2,10      
148 L 0,85 1,1 0,94      1,3 1,1 1,43      1,4 1,2 1,68      1,5 1,2 1,80      
MITTELWERT 0,88      1,21      1,56      1,95      
Day 4 Day 5 Day 6 Day7
No Tu Length Width Circ. Tu Length Width Circ. Tu Length Width Circ. Tu Length Width Circ.
140 R 1,35 1,75 2,36      1,2 1,55 1,86      1,3 1,65 2,15      1,2 1,15 1,38      
140 L 1,5 1,4 2,10      1,6 1,3 2,08      1,55 1,3 2,02      1,3 1,3 1,69      
143 R 1 0,95 0,95      
143 L 1 1 1,00      
144/145 R 1,25 1,1 1,38      1,4 1,4 1,96      1,4 1,2 1,68      1,2 1,1 1,32      
144/145 L 1,25 1,05 1,31      1,2 1,05 1,26      1,3 1,2 1,56      1,15 1,15 1,32      
147 R
147 L
156 R 0,65 0,55 0,36      1,05 1,05 1,10      
156 L 1,55 1,4 2,17      1,45 1,45 2,10      
MITTELWERT 1,45      1,73      1,85      1,43      
148 R 1,4 1,15 1,61      1,4 1,35 1,89      1,55 1,4 2,17      1,6 1,3 2,08      
148 L 1,5 1,35 2,03      1,7 1,45 2,47      1,85 1,4 2,59      1,55 1,2 1,86      
MITTELWERT 1,82      2,18      2,38      1,97      
Tu weight g
140 R
140 L 1,91
144/145 R 1,17
144/145 L 0,77
156 R
156 L
MITTELWERT 1,28
148 R 1,85
148 L 1,95
149 R 1,91
149 L 1,38
MITTELWERT 1,77
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a.                                                                                b.
 
 
 
 
 
 
 
 
 
Figure S1 (a) Treatment of mice with Aza. Decreased tumor growth was observed in treated 
mice compared with the untreated (PBS) control group. (b) Tumor weight measurements in 
treated (n=3) vs. untreated mice (n=4). Tumor weight and growth reduction was observed in the 
Aza treated mice. 
Figure S2 FACS analysis of Aza treated Xenograft tumors. More cells of treated Aza mice are 
present in the growth G1 phase. In the S-phase due to tumor activity there are more cells 
present in the untreated (PBS) then in treated mice, whereas Sub G1 phase shows almost same 
number of nuclei of apoptotic cells in treated and untreated mice. 
 
 
 
 
 
 
 
 
Figure S3 Protein analysis of DNMT1 after treatment with Aza. DNMT1 is depleted in the treated 
mice compared with the untreated (PBS), where the protein is still expressed.
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Figure S4 Immunohistochemistry Staining of Aza treated tumor tissues. In Aza treated mice 
(1C, 1D) there are more apoptotic areas compared to non-treated mice (1A, 1B).  Proliferation 
increases in untreated (2A, 2B) compared with lower proliferation rate in treated mice (2C, 2D). 
Differences in Caspase 3 expression cannot be observed in the both groups. 
 
 
 
 
 
 
51 
 
7.1.2 Xenograft 2 
 
 
Table S3 Measurements of tumor growth in Aza treated and untreated mice. 
                        
 
 
 
 
 
 
 
 
 
 
 
Table S4 Tumor weight measurements of Aza treated and control mice. 
Control mice (C) 
 
 
 
 
 
 
 
 
No. Tu Weight 605L 0,027
601R 0,1 MITTELWERT 0,011444444
601L 0 No. Tu Weight
602R 0 615R C 0,27
602L 0 615L C 0,23
603R 0 616R C 0,24
603L 0 616L C 0,44
604R 0,003 617R C 0,17
604L 0 617L C 0,13
605R 0 MITTELWERT 0,25
Aza Day 0  Day 1 Day 2
Tu Lenght Width Circ. Tu Lenght Width Circ. Tu Lenght Width Circ
601L 0 0 0 0 0 0 0 0 0
601R 0 0 0 0 0 0 0 0 0
602L 0 0 0 0 0 0 0 0 0
602R 0 0 0 0 0 0 0 0 0
603L 0 0 0 0 0 0 0 0 0
603R 0 0 0 0 0 0 0 0 0
604L 0 0 0 0 0 0 0 0 0
604R 0 0 0 0 0 0 0 0 0
605L 0,65 0,55 0,3575 0 0 0 0 0 0
605R 0 0 0 0 0 0 0 0 0
MITTELWERT 0,03575 0 0
Day 0  Day 1 Day 2
Control Tu Lenght Width Circ. Tu Lenght Width Circ. Tu Lenght Width Circ
615L 0,75 0,8 0,6 0,75 0,65 0,4875 0,85 0,75 0,6375
615R 0 0 0 0,8 0,85 0,68 0,8 0,85 0,68
616L 0,6 0,65 0,39 0,55 0,55 0,3025 0,6 0,6 0,36
616R 0 0 0 0 0 0 0 0,5 0
617L 0,75 0,75 0,5625 0,65 0,6 0,39 0,85 0,8 0,68
617R 0,6 0,65 0,39 0,65 0,6 0,39 0,75 0,7 0,525
MITTELWERT 0,32375 0,375 0,48042
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 a.                                                                               b. 
 
 
 
 
 
 
 
Figure S5 (a) Tumor growth measurement of Aza treated mice. Tumor growth is highly reduced 
in treated compared with untreated control. (b) Tumor weight is heavily decreased in treated 
mice (n=3) compared with the control group (n=6).   
 
Figure S6 Immunohistochemistry Staining of Aza treated tumor tissue. Increased apoptosis in 
treated mice (1C, 1D) compared with untreated control group (1A, 1B). Proliferation is also 
highly increased in untreated mice (2A, 2B) then in treated mice (2C, 2D). Caspase 3 activity is 
increased in treated (3C, 3D) mice compared with the untreated control group (3A, 3B). 
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7.1.3 Xenograft 3 
  
Table S5 Tumor growth measurements of Aza treated mice. 
 
 
 
 
 
 
 
 
 
Table S6 Measurements of tumor weight in Aza treated and control mice. 
 
 
 
 
 
 
 
Aza Early Tu Weight L Tu Weight R MITTELWERT
C 8978 0,14 0 0,05825
C 8979 0,093 0
Aza Late
C 89 77 0,34 0,2
C 89 80 0,056 0 0,1405
C 89 81 0,137 0,11
Control
C 89 51 0,77 0,56
C 89 76 0,36 0,37 0,486666667
C 89 82 0,86 0
Day 1 Day 3 Day5 Day7
Aza early Tu R Lenght Width Circ.  Tu R Lenght Width Circ.  Tu R Lenght Width Circ.  Tu R Lenght Width Circ.  
f   C89 52 R 0 0 0 0 0 0 0 0 0 0 0 0
f   C89 52 L 0 0 0 0 0 0 0 0 0 0 0 0
m C89 78 R 0 0 0 0,7 0,65 0,455 0 0 0 0 0 0
m C89 78 L 0 0 0 0 0 0 0,8 0,75 0,6 0,7 0,6 0,42
m C8979/C8753 R 0 0 0 0 0 0 0 0 0 0 0 0
m C8979/C8753 L 0 0 0 0 0 0 0 0 0 0 0
MITTELWERT 0 0,07583333 0,1 0,07
Day 1 Day 3 Day5 Day7
Aza late Tu R Lenght Width Circ.  Tu R Lenght Width Circ.  Tu R Lenght Width Circ.  Tu R Lenght Width Circ.  
f C89 84R 0 0 0 0 0 0 0 0 0 0 0 0
f C89 84 L 0,6 0,6 0,36 0,6 0,6 0,36 0,6 0,8 0,48 0 0 0
m C89 77R 0 0 0 0,8 0,5 0,4 0,8 0,65 0,52 0,9 0,65 0,585
m C89 77L 0 0 0 0,5 0,85 0,425 0,6 1 0,6 0,75 1 0,75
m C89 80 R 0 0 0 0 0 0 0 0 0 0 0
m C89 80 L 0 0 0 0 0 0 0,6 0,55 0,33 0,6 0,55 0,33
m C89 81 R 0 0 0 0,7 0,7 0,49 0,8 0,85 0,68 0,85 0,85 0,7225
m C89 81 L 0 0 0 0,6 0,6 0,36 0,65 0,6 0,39 0,65 0,75 0,4875
MITTELWERT 0,045 0,254375 0,375 0,47916667
Day 1 Day 3 Day5 Day7
Control Tu R Lenght Width Circ.  Tu R Lenght Width Circ.  Tu R Lenght Width Circ.  Tu R Lenght Width Circ.  
 f C8951 R 0,65 0,55 0,33 0,7 0,65 0,455 0,95 1 0,95 1,1 1,15 1,265
 f C8951 L 0 0 0 0,6 0,6 0,36 0,8 0,8 0,64 0,95 1,1 1,05
m C89 76 R 0 0 0 0,75 0,7 0,525 0,8 0,75 0,6 1 0,85 0,85
m C89 76 L 0 0 0 0,6 0,6 0,36 0,8 0,8 0,64 1 1,05 1,05
m C89 82 R 0 0 0 0 0 0 0 0 0 0 0 0
m C 8982 L 0 0 0 0,9 0,8 0,72 0,95 1,05 0,9975 1,1 1,05 1,155
MITTELWERT 0,055 0,40333333 0,63791667 0,895
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7.2 MS-275 treatment  
7.2.1 Xenograft 1  
 
Table S7 Tumor growth measurements in MS-275 treated mice. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table S8 Tumor weight measurements in MS-275 treated mice. 
 
 
 
 
139 R 0,9 0,75 0,68      0,85 0,8 0,68      1 0,75 0,75      1,1 0,95 1,05      
139 L 0,9 1 0,90      1,25 1,15 1,44      1,25 0,95 1,19      1,4 1,1 1,54      
141/142 R 0,8 0,85 0,68      1 1 1,00      1,1 1 1,10      1,05 1,2 1,26      
141/142 L 1 0,7 0,70      1,1 1,35 1,49      1,05 1,3 1,37      1,05 1,15 1,21      
146 R 1,1 0,7 0,77      1 1 1,00      1,2 0,9 1,08      1,4 1 1,40      
146 L 0 0 -         0 0 -         0,8 0,7 0,7 0,6
151/152 R 1,3 1 1,5 1,25 1,3 1,05 1,5 1,05
151/152 L 0,6 0,85 0,51      0,85 0,75 0,64      0,9 0,85 0,77      1 0,75 0,75      
155R 1,1 0,9 0,99      0,9 0,8 0,72      0,9 0,85 0,77      1 0,8 0,80      
155L 0,8 0,8 0,64      0,9 0,8 0,72      0,9 0,9 0,81      0,9 0,9 0,81      
MITTELWERT 0,65      0,85      0,98      1,10      
149 R 0,9 0,7 0,63      1,1 0,9 0,99      1,15 1,4 1,61      1,6 1,25 2,00      
149 L 0,8 0,8 0,64      1,3 1,1 1,43      1,1 1 1,10      1,3 1,1 1,43      
MITTELWERT 0,64      1,21      1,36      1,72      
Day 4 Day 5 Day 6 Day7
No Tu Length Width Circ. Tu Length Width Circ. Tu Length Width Circ. Tu Length Width Circ.
139 R 1 0,95 0,95      1,1 1,05 1,16      1,2 1,2 1,44      1 1,8 1,80      
139 L 1,45 1,2 1,74      1,4 1,4 1,96      1,6 1,2 1,92      1,6 1,2 1,92      
141/142 R 1,3 1,1 1,43      1,3 1,3 1,69      1,45 1,35 1,96      1,4 1,55 2,17      
141/142 L 1 1,2 1,20      1,2 1,3 1,56      1,3 1,2 1,56      1,75 1,85 3,24      
146 R 1,45 1,05 1,52      1,45 1,2 1,74      1,4 1,2 1,68      1,9 1,3 2,47      
146 L 1,5 1,35 0,8 0,65 1,05 0,9 0,9 0,75 0,68      
151/152 R 1,45 1 1,4 1,35 1,55 1,55 2,4 1,95
151/152 L 0,95 0,85 0,81      1,05 0,95 1,00      1,15 1 1,15      1,2 1,1 1,32      
155R 1,1 1 1,10      0,95 0,9 0,86      1 1,2 1,20      
155L 1,05 0,9 0,95      1 1,05 1,05      1,05 1,05 1,10      
MITTELWERT 1,21      1,38      1,50      1,94      
149 R 1,6 1,25 2,00      1,75 1,4 2,45      1,8 1,6 2,88      2,1 1,9 3,99      
149 L 1,3 1,2 1,56      1,3 1,3 1,69      1,5 1,35 2,03      1,55 1,4 2,17      
MITTELWERT 1,78      2,07      2,45      3,08      
Tumor Weight
No Tumor weight/g
139 R 1,32
139 L 2,74
141/142 R 1,23
141/142 L 2,15
146 R 2,29
151/152 L 0,65
146 L 0,54 excluded because no tumor day0
151/152 R 3,3 excluded because tumor too big on day 0
155R 1,31 excluded because one day less therapy
155L 0,51 excluded because one day less therapy
MITTELWERT 1,73
149 R 1,91
149 L 1,38
148 R 1,85
148 L 1,95
MITTELWERT 1,7725
55 
 
8. Abbreviations 
AKTv         akt murine thymoma viral oncogene homolog  
ALK           anaplastic lymphoma kinase 
APC          adenomatous polyposis coli 
ARF           alternate reading frame 
CASP3      Caspase 3 
CCND1      CYCLIN D1  
C-JUN        jun proto-oncogene 
DNMT1      DNA (cytosine-5-)-methyltransferase 1 
DNMT2      tRNA (cytosine-5-)-methyltransferase 2 
DNMT3a    DNA (cytosine-5)-methyltransferase 3 alpha 
DNMT3b    DNA (cytosine-5-)-methyltransferase 3 beta 
DNMT3L    DNA (cytosine-5-)-methyltransferase 3-like 
ERK            elk-related tyrosine kinase 
EZH2          enhancer of zeste homolog 2 
GASC1       lysine (K)-specific demethylase 4C 
GSTP1       glutathione S-transferase pi 1 
IRS1           insulin receptor substrate-1 
JAG1          Jagged  
JAK2          Janus kinase 2 
JAK3          Janus kinase 3 
Jmjd3         lysine (K)-specific demethylase 6B 
LEF            lymphoid enhancer-binding factor 1 
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LSD1          lysine (K)-specific demethylase 1A 
MAPK        mitogen-activated protein kinase 
MYC v       myc myelocytomatosis viral oncogene homolog (avian) 
NFATC      nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1 
NPM1        nucleophosmin 
NSD1        nuclear receptor binding SET domain protein 1 
p16            cyclin-dependent kinase inhibitor 2A 
p21            cyclin-dependent kinase inhibitor 1A 
p27            cyclin-dependent kinase inhibitor 1B 
p53            tumor protein p53  
PI3-K         phosphoinositide-3-kinase, catalytic, gamma polypeptide 
PLCγ         phospholipase C, gamma  
PTEN        phosphatase and tensin homolog 
RASSF1A Ras association (RalGDS/AF-6) domain family member 1 
Rb             Retinoblastoma 
SHC       SH2 domain-containing transforming protein  
SHP1        protein tyrosine phosphatase, non-receptor type 6 
SRC v       src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (avian) 
STAT 3     suppressor of cytokine signaling 3 
STAT5B    signal transducer and activator of transcription 5B 
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TCF          T-cell factor 
WNT2       wingless-type MMTV integration site family member 2 
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